“Pharma is a better dollar play than IT in the current environment, driven by three tailwinds: FII flows, product-specific opportunities, and CDMO segment strength. Domestic healthcare, hospitals, and diagnostics also offer optimism.”
Sunil Subramaniam’s track record: 14 graded calls · 95% CI 12–55%
Nifty PharmaBullishCalled 23 Jun 2026Graded 25 Jul 2026
Nifty Pharma increased from ₹25018.95 to ₹25548.15, a gain of 2.12% in 30 days.
Read the original articleSee Sunil Subramaniam’s full track record